Biotech Values

[DewDiligence]

Attention investors in the HCV arena…

MRK holds its annual R&D Day presentation tomorrow (Tuesday) at 8:30 am ET:

http://www.merck.com/investors/events-and-presentations/home.html

For those who follow the HCV arena, there could be material updates on the Boceprevir, MK-7009, and MK-3281 programs.

I’ll be paying particular attention to what is said about MK-3281, a non-nuke where the abstract at the 2009 AASLD hinted at a possible safety issue. From #msg-42093301:

One patient discontinued due to an AE of myoclonus on study Day 2 of approximately 1.5 h in duration, preliminarily judged possibly-related to MK-3281 and rated of severe intensity.

Despite the severe intensity, this incident was tallied as an AE rather than an SAE.